The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available on ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies underwa ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.

Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET. Company Participants. Katie Hogan - Senior Director-Corporate Communications and Investo ...

Five years later, and in the face of a potentially changing healthcare landscape again, Dr. Lynch is ever committed and steadfast in his vision for the NCI-designated cancer center. He recently shared ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...

Glenda Gray, program director of a research consortium, talked with STAT about the impact of the funding freeze on an HIV ...